Orexigen Therapeutics Inc

Orexigen Therapeutics — Investor Presentation (June 2009)

37 slides from Orexigen Therapeutics's investor presentation, Jun 2, 2009

  1. Slide 1: Investor Update June 2009

    Investor Update June 2009 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “assuming” and similar expressions are intended to identify forward-looking statements. Thes

  3. Slide 3: Orexigen: Poised for Transformation from Phase III to a Commercial Biotech

    Orexigen : Poised for Transformation from Phase III to a Commercial Biotech

  4. Slide 4: A Great Team that Can Execute on Core Strategies

    A Great Team that Can Execute on Core Strategies President & CEO: Michael Narachi 20 year veteran of Amgen; wide ranging experience including global team leader, Neupogen; head of corporate strategic planning; head of licensing and business development; COO of Amgen Biopharma, VP development Japan a

  5. Slide 5: Comprehensive, Defensible IP Position with Exclusivity Beyond the Next Decade

    Comprehensive, Defensible IP Position with Exclusivity Beyond the Next Decade Contrave Empatic Composition Issued (2025) Issued (2023) Methods of use Issued (2024) Issued (2023) In addition: European Contrave composition/use patent issued (22 EP countries) US Patent for zonisamide used alone or in c

  6. Slide 6: Contrave Program Overview

    Contrave ® Pro g ram Overview (bupropion SR / naltrexone SR)

  7. Slide 7: What is Driving the Obesity Epidemic?

    What is Driving the Obesity Epidemic? Obesity rate reflects a change in environment, not genes Availability of quick, cheap and unhealthy foods that are easily accessible Emphasizes the need for an effective therapy that addresses the behavioral aspects of consumption, including reward and reinforce

  8. Slide 8: Contrave Rational Pharmacology: Dual Approach Addresses Hypothalamic and Reward Systems

    Contrave Rational Pharmacology: Dual Approach Addresses Hypothalamic and Reward Systems Contrave combines two well - established drugs in a proprietary sustained release formulation Bupropion acts on the weight control circuit by stimulating the POMC neuron Naltrexone prevents inhibition of POMC neu

  9. Slide 9: Contrave Phase IIb Trial Design

    Contrave Phase IIb Trial Design Study Design: 24 week multi-center (7), randomized, double-blind, placebo-controlled dose ranging study with an additional 24 week open- label extension for bupropion and Contrave subjects Primary Outcome: 24 week weight loss (%) from baseline (ITT-LOCF) Patient Popul

  10. Slide 10: Contrave Phase IIb Indicates Synergy of Combination

    Contrave Phase IIb Indicates Synergy of Combination *Weight loss at 24 weeks (for comparison only) *Weight loss at 24 weeks (for comparison only) Intent-to-Treat Population Completer Population Placebo (N=84) Nal (N=49) Bup (N=57) NB48 (N=54) NB32 (N=63) NB16 (N=54) Contrave ® Placebo (N=84) Nal (N=

  11. Slide 11: Robust Efficacy on Co-primary Endpoints in Phase IIb

    Robust Efficacy on Co-primary Endpoints in Phase IIb -0.8% -1.2% -2.7% -5.5% -6.6% -5.0% -8.0% -7.0% -6.0% -5.0% -4.0% -3.0% -2.0% -1.0% 0.0% Placebo (N=84) Nal (N=49) Bup (N=57) NB48 (N=54) NB32 (N=63) NB16 (N=54) Weight loss at 24 weeks (for comparison only) Weight Loss from Baseline (48 Weeks, IT

  12. Slide 12: Contrave Phase IIb Mean Weight Loss over Weeks

    Contrave Phase IIb Mean Weight Loss over 48 Weeks (Observed Case Analysis) Bupropion SR 400mg + Naltrexone IR 48mg Bupropion SR 400mg + Placebo -1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -12 -13 Bupropion SR 400mg + Naltrexone IR 32mg Bupropion SR 400mg + Naltrexone IR 16mg BL Placebo Only Naltrexone IR 48m

  13. Slide 13: Contrave Phase IIb Demonstrated Acceptable Safety and Tolerability Profile

    Contrave Phase IIb Demonstrated Acceptable Safety and Tolerability Profile NO serious adverse events attributed to Contrave Adverse events consistent with profiles of constituent drugs Most common adverse events leading to discontinuation: Nausea, dizziness, headache, irritability Overall rate of di

  14. Slide 14: Broad Phase III Program Designed for Regulatory and Commercial Success

    Broad Phase III Program Designed for Regulatory and Commercial Success Phase III Trial Size Status NB-301 (NB-16, NB-32, Plc) 1,739 Expect data Q3 2009 NB-302 (Behavior Modification) Completed NB-303 (NB-32/plc, Dose Escalation) 1,496 Expect data Q3 2009 NB-304 (Co-morbid Diabetes) Expect data Q3 20

  15. Slide 15: NB-302: Contrave Therapy Added Significant Benefits to Intensive Behavior Modification

    NB-302: Contrave Therapy Added Significant Benefits to Intensive Behavior Modification Design: Bupropion SR 360mg / naltrexone SR 32mg (NB32) vs. placebo, with underlying behavior modification regimen in a 3:1 randomization across 9 U.S. sites Behavior Modification: Restrictive diet, 30-60 mins/day

  16. Slide 16: NB-302: Contrave Therapy was Significantly Additive to Intensive Behavior Modification Protocol

    NB-302: Contrave Therapy was Significantly Additive to Intensive Behavior Modification Protocol ITT analysis set: all randomized subjects with baseline and at least one post-baseline measurement on study drug (Week 56 LOCF) Completer analysis set: all randomized subjects with baseline and Week 56 me

  17. Slide 17: NB-302: Contrave Therapy Significantly Increased Likelihood of Double-digit Weight Loss

    NB-302: Contrave Therapy Significantly Increased Likelihood of Double-digit Weight Loss ITT analysis set: all randomized subjects with baseline and at least one post-baseline measurement on study drug (Week 56 LOCF) Completer analysis set: all randomized subjects with baseline and Week 56 measuremen

  18. Slide 18: NB-302: Improvements in Secondary Endpoints and Cardiovascular Risk

    NB-302: Contrave Therapy Drove Improvements in Secondary Endpoints and Measures of Cardiovascular Risk * p-value <0.01 between NB32 and placebo for non-cardiovascular measures Pulse increased approx 1.05 bpm for ITT; <0.1 bpm for completers Waist circumference Fasting triglycerides Fasting HDL chole

  19. Slide 19: NB-302: Acceptable Safety and Tolerability Profile

    NB-302: Acceptable Safety and Tolerability Profile Discontinuation Rates Due to Adverse Events in NB-302 10 most common reasons for discontinuation due to adverse events * p-value <0.05 between NB32 and placebo Treatment Group Placebo NB32 Number of Subjects Discontinuation due to AEs through week 2

  20. Slide 20: OREXIGEN*

    > a OREXIGEN*

  21. Slide 21: NB-302: Nausea and Other Tolerability AEs Appear Manageable in the Commercial Setting

    NB-302: Nausea and Other Tolerability AEs Appear Manageable in the Commercial Setting Safety analysis set: all randomized subjects who received tablet of study medication and had investigator contact/assessment at any time after the start of study treatment Consistent with Phase II results, nausea i

  22. Slide 22: NB-302 Trial Demonstrated Attractive Blend of Efficacy, Safety and Tolerability

    NB-302 Behavior Modification Trial Demonstrated Attractive Blend of Efficacy, Safety and Tolerability Efficacy Demonstrated additive effect of Contrave to rigorous behavior modification regimen Double-digit average weight loss among completers Over half of completers lost 10% of body weight Translat

  23. Slide 23: Broad Phase III Program Designed for Regulatory and Commercial Success

    Broad Phase III Program Designed for Regulatory and Commercial Success Phase III Trial Size Status NB-301 (NB-16, NB-32, Plc) 1,739 Expect data Q3 2009 NB-302 (Behavior Modification) Completed NB-303 (NB-32/plc, Dose Escalation) 1,496 Expect data Q3 2009 NB-304 (Co-morbid Diabetes) Expect data Q3 20

  24. Slide 24: Empatic

    Empatic ™ (bupropion SR / zonisamide SR) Additional opportunity in obesity with a late-stage clinical asset

  25. Slide 25: Empatic Phase IIb Trial Designed to Optimize Combination Doses

    Empatic Phase IIb Trial Designed to Optimize Combination Doses Rationale for ZB-201: Combination of bupropion SR and zonisamide SR to harness the powerful AgRP effects of zonisamide in this more aggressive combination Objective: Identify optimal dose ratio using novel SR zonisamide formulation in a

  26. Slide 26: Empatic Weight Loss through Weeks

    Empatic Weight Loss through 24 Weeks (Observed Case Analysis) -11% -10% -9% -8% -7% -6% -5% -4% -3% -2% -1% 0% Study Week Placebo Z120/B280 Z120/B360 Z240/B280 Z240/B360 Z360/B280 Z360/B360

  27. Slide 27: Discontinuation Rates Due to AE in Phase IIb were not Significantly Different from Placebo

    Discontinuation Rates Due to AE in Phase IIb were not Significantly Different from Placebo Treatment Group Plc Z120/ B280 Z120/ B360 Z240/ B280 Z240/ B360 Z360/ B280 Z360/ B360 Number Of Subjects Discontinuations @ 24 weeks due to AE 9.1% 10.3% 9.2% 10.0% 20.7% 16.9% 16.9% Anxiety 1.1% 0% 1.1% 1.1%

  28. Slide 28: Exciting Empatic Phase IIb Results Drove Continued Development

    Exciting Empatic Phase IIb Results Drove Continued Development Rationale for ZB-202: Assess two different dosages of Empatic based on results of prior Phase IIb clinical trial Objective: Demonstrate superiority over individual constituents Sample Size: 729 randomized subjects; 20 sites Duration: 28

  29. Slide 29: Commercial Considerations

    Commercial Considerations

  30. Slide 30: Pharmacotherapy Needed to 'Bridge the Gap' Between Lifestyle Intervention and Surgery

    Pharmacotherapy Needed to ‘Bridge the Gap’ Between Lifestyle Intervention and Surgery

  31. Slide 31: Obesity: Why Reimburse?

    Obesity: Why Reimburse? “Thus, the question as to whether intentional weight loss improves life span has been answered, and the answer appears to be a resounding yes.”

  32. Slide 32: Roadmap to Reimbursement

    Roadmap to Reimbursement “State of the art" approach to commercial coverage Identify key payors Stratify and target by plan size, influence over pharmacy utilization, current policy and role of medical management in developing disease state-focused programs Organize the evidence Collect supporting c

  33. Slide 33: Identifying Target-rich Physician Segments is Key to Successful Commercialization

    Identifying Target-rich Physician Segments is Key to Successful Commercialization Number of Prescribers Unique Insights in Each Segment Drive Commercial Strategy Bariatric Surg Endos OB/Gyns Cards Psychs Aesthetic Derms Broad PCP Audience

  34. Slide 34: Contrave Offers Unique Benefits for Obese Patients: Opportunity for Market Expansion

    Contrave Offers Unique Benefits for Obese Patients Opportunity for Market Expansion Source: Orexigen Quantitative Market Research, November 2007 BMI 25-29 BMI 30-39 BMI 40+ 49% 40% 27% 25% Eating Behavior History of Depression

  35. Slide 35: Capitalized through NDA Submission with Right-size Organization and Burn Rate

    Capitalized through NDA Submission with Right-size Organization and Burn Rate Cash and equivalents $64.7 million Long-term debt $15.1 million Shares outstanding 34.7 million Options outstanding 4.0 million

  36. Slide 36: Orexigen: Poised for Transformation from Phase III to a Commercial Biotech

    Orexigen : Poised for Transformation from Phase III to a Commercial Biotech Results from all Contrave Phase III trials available Q3 2009 Results for Empatic Phase IIb available in 2H 2009 Worldwide rights to all products still intact Capitalized through NDA submission with right-size organization an

  37. Slide 37: Orexigen

    Cs OREXIGEN

Orexigen Therapeutics — Investor Presentation (June 2009) on 6ix